31.60

1.19% -0.38

Harmony Biosciences Holdings Inc (HRMY)

Überblick Nachrichten Preisverlauf Optionskette Financials Warum fällt HRMY? Forum Prognose

Schlusskurs vom Vortag:

$31.98

Offen:

$31.94

24-Stunden-Volumen:

672.44K

Relative Volume:

0.97

Marktkapitalisierung:

$2.06B

Einnahmen:

$681.88M

Nettoeinkommen (Verlust:

$122.63M

KGV:

14.98

EPS:

2.11

Netto-Cashflow:

$220.18M

1W Leistung:

-1.03%

1M Leistung:

-8.41%

6M Leistung:

-8.17%

1J Leistung:

+4.74%

1-Tages-Spanne:

$31.48

$32.23

1-Wochen-Bereich:

$31.25

$32.46

52-Wochen-Spanne:

$26.47

$41.61

Harmony Biosciences Holdings Inc Stock (HRMY) Company Profile

Firmenname

Harmony Biosciences Holdings Inc

Sektor

Healthcare (1173)

Branche

Biotechnology (661)

Telefon

(484) 539-9800

Adresse

630 W GERMANTOWN PIKE, PLYMOUTH MEETING

Mitarbeiter

268

Twitter

Nächster Verdiensttermin

2024-10-29

Neueste SEC-Einreichungen

HRMY's Discussions on Twitter

Vergleichen Sie HRMY mit anderen Aktien

Aktien	Preis	Marktkapitalisierung	Umsatz	Nettogewinn	Free Cashflow	ENV
HRMY Harmony Biosciences Holdings Inc	31.60	2.06B	681.88M	122.63M	220.18M	2.11
VRTX Vertex Pharmaceuticals Inc	445.20	115.95B	11.10B	-988.90M	-1.26B	-3.92
REGN Regeneron Pharmaceuticals Inc	525.00	56.52B	14.09B	4.50B	2.96B	39.28
ALNY Alnylam Pharmaceuticals Inc	326.09	39.44B	2.35B	-269.70M	-75.39M	-2.09
ARGX Argen X Se Adr	551.22	35.14B	2.58B	1.06B	-1.28B	16.33
ONC Beone Medicines Ltd Adr	242.07	28.51B	3.81B	-644.79M	-669.77M	-6.24

Harmony Biosciences Holdings Inc Stock (HRMY) Upgrades & Downgrades

Datum	Aktion	Analytiker	Ratingänderung
2025-06-02	Fortgesetzt	Oppenheimer	Outperform
2025-02-11	Eingeleitet	Deutsche Bank	Buy
2024-12-17	Eingeleitet	H.C. Wainwright	Buy
2024-10-10	Fortgesetzt	Raymond James	Outperform
2024-09-10	Eingeleitet	UBS	Buy
2024-06-21	Eingeleitet	Citigroup	Buy
2024-01-02	Herabstufung	BofA Securities	Neutral → Underperform
2023-09-25	Herabstufung	Goldman	Neutral → Sell
2023-09-07	Eingeleitet	Berenberg	Buy
2023-04-20	Eingeleitet	BofA Securities	Neutral
2022-10-14	Hochstufung	Janney	Neutral → Buy
2022-10-14	Hochstufung	Jefferies	Hold → Buy
2022-08-03	Herabstufung	Jefferies	Buy → Hold
2022-07-13	Herabstufung	Goldman	Buy → Neutral
2022-07-07	Eingeleitet	Mizuho	Buy
2022-04-14	Eingeleitet	Cantor Fitzgerald	Overweight
2021-12-01	Eingeleitet	Oppenheimer	Outperform
2021-11-04	Eingeleitet	Raymond James	Outperform
2021-09-23	Eingeleitet	Needham	Buy
2021-03-29	Hochstufung	Goldman	Neutral → Buy
2020-09-14	Eingeleitet	Goldman	Neutral
2020-09-14	Eingeleitet	Jefferies	Buy
2020-09-14	Eingeleitet	Piper Sandler	Overweight

Alle ansehen

Harmony Biosciences Holdings Inc Aktie (HRMY) Neueste Nachrichten

Jun 16, 2025

Lupin Concedes To Harmony On Generic Wakix With 2030 Launch Agreement - insights.citeline.com

Jun 16, 2025

Harmony Biosciences Presents Promising Preclinical Data for Novel Narcolepsy Treatment - MyChesCo

Jun 16, 2025

Jun 15, 2025

Rhumbline Advisers Increases Holdings in Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY) - Defense World

Jun 15, 2025

Jun 14, 2025

Harmony Biosciences to begin human trials of narcolepsy drug in 2025 By Investing.com - Investing.com South Africa

Jun 11, 2025

Harmony Biosciences to begin human trials of narcolepsy drug in 2025 - Investing.com Canada

Jun 11, 2025

HRMY: Harmony Biosciences Shows Promising Preclinical Data for BP1.15205 | HRMY Stock News - GuruFocus

Jun 11, 2025

Harmony Biosciences (HRMY) Presents Preclinical Data Demonstrating Significant Wake-Promoting and Cataplexy-Suppressing Effects of BP1.15205 - StreetInsider

Jun 11, 2025

Harmony Biosciences Presents Preclinical Data Demonstrating Significant Wake-Promoting and Cataplexy-Suppressing Effects of BP1.15205 in Narcolepsy at SLEEP 2025 - Business Wire

Jun 11, 2025